Celcuity (NASDAQ:CELC) Sees Strong Trading Volume – Should You Buy?

Celcuity, Inc. (NASDAQ:CELC) shares saw unusually-strong trading volume on Thursday . Approximately 1,413,782 shares traded hands during trading, an increase of 51% from the previous session’s volume of 935,131 shares.The stock last traded at $91.22 and had previously closed at $88.95.

Celcuity News Summary

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Celcuity and a $145 price target, while publishing 2027 EPS estimates that turn positive by late 2027, suggesting confidence in the long-term earnings outlook. Article Title
• Positive Sentiment: Coverage following the company’s ASCO data argues the selloff was overdone, highlighting Phase 3 VIKTORIA-1 results that showed gedatolisib’s strong efficacy versus standard-of-care treatment in advanced breast cancer, which could support future approval and blockbuster sales potential. Article Title
• Neutral Sentiment: Celcuity priced an upsized $500 million convertible note offering due 2032, providing a substantial cash cushion for development and potential commercialization, but also adding future dilution and leverage concerns. Article Title
• Negative Sentiment: Earlier detailed VIKTORIA-1 readouts disappointed some investors and triggered a steep selloff, with headlines saying the results missed lofty expectations despite still showing benefit, which is likely the main reason for recent volatility. Article Title

Analysts Set New Price Targets

A number of brokerages recently issued reports on CELC. Weiss Ratings cut Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 19th. Citigroup reissued a “market outperform” rating on shares of Celcuity in a report on Thursday, May 28th. Guggenheim reissued a “buy” rating on shares of Celcuity in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $157.00 target price on shares of Celcuity in a report on Friday, May 15th. Finally, Macquarie Infrastructure set a $160.00 target price on Celcuity in a report on Thursday, May 28th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $152.09.

Celcuity Stock Performance

The firm has a fifty day moving average of $122.64 and a 200-day moving average of $111.55. The stock has a market capitalization of $4.40 billion, a price-to-earnings ratio of -23.17 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.96 EPS for the current year.

Insiders Place Their Bets

In other news, Director Richard E. Buller sold 9,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. The trade was a 57.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 37,000 shares of company stock valued at $5,111,950. Insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of institutional investors have recently made changes to their positions in the stock. NEA Management Company LLC raised its holdings in shares of Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Celcuity in the fourth quarter valued at $310,302,000. Soleus Capital Management L.P. grew its position in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the period. Vanguard Group Inc. grew its position in shares of Celcuity by 10.7% in the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock valued at $227,351,000 after purchasing an additional 220,386 shares during the period. Finally, State Street Corp grew its position in shares of Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after purchasing an additional 914,887 shares during the period. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.